Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366271 | 0.89 | MAPK14 (0.54) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL14366273 | 0.88 | MAPK14 (0.51) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL1137635 | 0.84 | MET (0.71) | METMAPK14KDRCSF1RPDGFRB | |
| SCHEMBL4334234 | 0.84 | MAPK14 (0.47) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL4324391 | 0.83 | MET (0.51) | METMAPK14KDRMAPK13PDGFRB | |
| SCHEMBL4335860 | 0.83 | KDR (0.52) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL14366279 | 0.83 | KDR (0.52) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL4329494 | 0.83 | MET (0.56) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL13861489 | 0.82 | KDR (0.49) | METMAPK14KDRMAPK13CSF1R | |
| SCHEMBL9958743 | 0.82 | KDR (0.51) | METMAPK14KDRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | MET 2/4885MAPK14 2269/4885KDR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.